Metabolism of ticagrelor in patients with acute coronary syndromes

Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic activation to exert its antiplatelet action. Still, ticagrelor is extensively metabolized...

Descripción completa

Detalles Bibliográficos
Autores principales: Adamski, Piotr, Buszko, Katarzyna, Sikora, Joanna, Niezgoda, Piotr, Barańska, Malwina, Ostrowska, Małgorzata, Paciorek, Przemysław, Navarese, Eliano P., Gorog, Diana A., Kubica, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078957/
https://www.ncbi.nlm.nih.gov/pubmed/30082687
http://dx.doi.org/10.1038/s41598-018-29619-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078957/
https://www.ncbi.nlm.nih.gov/pubmed/30082687
http://dx.doi.org/10.1038/s41598-018-29619-9

Ejemplares similares